Menu

One step ahead of the other
Discover the convenience of taking on Miglustat Dipharma in the new wallet created especially for you
Discover the convenience of taking on Miglustat Dipharma in the new wallet created especially for you
Morbus Gaucher Type 1 is a rare genetic condition caused by a problem in the body’s ability to break down certain fatty substances. This happens because of a missing or malfunctioning enzyme called glucocerebrosidase. When this enzyme doesn’t work as it should, fatty substances start to build up in specific cells, known as Gaucher cells. These cells accumulate in different parts of the body, particularly in the liver, spleen, and bone marrow, which can lead to a variety of symptoms.
One of the most noticeable signs of Gaucher Type 1 is an enlarged spleen or liver, which can make the abdomen appear swollen or distended. This can sometimes cause discomfort or pressure in the belly. Another common issue is bone involvement, where individuals might experience pain, reduced bone density, or fractures, making their bones more fragile over time. Additionally, the condition often affects blood counts, leading to anemia (low red blood cells), which can cause fatigue and weakness, as well as a tendency to bruise easily or experience frequent nosebleeds.
Niemann-Pick Type C (NPC) is a rare genetic disorder that affects the body’s ability to transport cholesterol and other lipids (fats) inside cells. This occurs due to a malfunction in certain proteins that are responsible for moving these lipids to the correct places within the cells. When these proteins don’t function properly, lipids accumulate in various organs, particularly the liver, spleen, brain, and lungs.
One of the main issues related to NPC is its impact on the nervous system. People with this condition may experience problems with movement and coordination (known as ataxia), difficulty with speech and understanding, and cognitive decline. Additionally, the liver and spleen can become enlarged, causing swelling and discomfort in the abdomen. As the disease progresses, people may also face difficulties with swallowing and breathing due to the involvement of other organs.
Miglustat Dipharma is now avaible in the practical wallet packaging.
Your patients can manage their medication more easily and have a clearer overview of the tablets they have taken.
Thanks to these benefits, treatment compliance could improve. In addition, the multilingual wallet makes it easier to supply all patients across Europe, increasing the availability of Miglustat Dipharma. This allows you to focus on what really matters: providing the best possible care for your patients.
FAQ
White hard capsules. Miglustat Dipharma can be taken with or without taken with or without food.
Take the next capsule at the usual time. Do not take a double dose to make up for a forgotten dose.
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. Tell your doctor if you are taking medicines containing imiglucerase, which are sometimes used at the same time as Miglustat Dipharma. They may lower the amount of Miglustat Dipharma in your body.
If you take more capsules than you were told to, consult your doctor immediately.
Do not stop taking Miglustat Dipharma without talking to your doctor.
This medicinal product does not require any special storage conditions.
Every day our top priority is taking care of people: patients, partners, employees. We provide high-quality drugs with improved properties such as an enhanced stability, to those who suffer from congenital metabolic disorders. We continuously listen to patients, parents, patient associations and physicians to learn about their needs and work on identifying sustainable solutions together. Thanks to our partners, we are able to reach patients all over the world, meeting unmet medical needs while keeping affordable prices.